about
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupClose relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreasHuman breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activityOsteonecrosis in children with acute lymphoblastic leukemiaCoagulation complications following traumaAccessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitorIncreased expression of urokinase plasminogen activator and its cognate receptor in human seminomasDecreased fibrinolytic activity in juvenile chronic arthritisAbnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitisType 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoterThrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance.Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).Reduced fibrinogen, fibrinolytic biomarkers, and physical parameters after a weight-loss program in obese subjectsRegulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-betaPlasminogen activators in normal tissue and carcinomas of the human oesophagus and stomachSecretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro.A glycosylation-deficient endothelial cell mutant with modified responses to transforming growth factor-beta and other growth inhibitory cytokines: evidence for multiple growth inhibitory signal transduction pathways.Periodicity in the levels of serum plasminogen activator inhibitor-1 is a robust prognostic factor for embryo implantation and clinical pregnancy in ongoing IVF cyclesThe addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expressionBleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.Fibrinolysis and the control of blood coagulation.Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.Vascular biology of metabolic syndromePlasminogen activator inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice.Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation.Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptorModulation of NF-κB-dependent gene transcription using programmable DNA minor groove bindersAbnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic diseasePrognostic role of urokinase-type plasminogen activator in human gliomas.Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factorPlasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysisRole of hypoxia-inducible transcription factors 1alpha and 2alpha in the regulation of plasminogen activator inhibitor-1 expression in a human trophoblast cell lineProteolytic-antiproteolytic balance and its regulation in carcinogenesis.Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cellsThe majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.A case of severe pulmonary thromboembolism in a young male with klinefelter syndromeThe effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assaysTumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
P2860
Q24656610-856C9D7C-F8DC-466F-90B4-389DAE5582E5Q24796861-107C063B-8D0C-4D3F-BBD8-D5971E584EF7Q24803810-74D17743-B69B-482E-AEC0-B9180520EB6AQ28066799-F6E4E12A-9A2E-43E9-9962-89E556DB23D8Q28072443-24E7F2C2-0A4F-4299-8CA3-F46B1FB085C4Q28647054-C494EE73-5612-46EF-BCCA-343D9608CCFCQ33559079-18EC1B0A-0B73-48B3-81CE-40619E8B6327Q33563211-9E4A6802-DFC9-4484-ABBC-BACDA3C8D519Q33565749-55063B8D-4E53-4CE4-9948-AF24F8C082DDQ33635406-B767EEA5-E68D-4F14-B016-9E81A32840A6Q33882773-DA9C9FCE-D65E-45CD-BD50-5E258BCA9679Q33883207-FBD6134D-98DB-41B4-A7CC-3812440A7EA6Q34153366-40ABAEF0-B469-4F2B-97F2-C49B6FEB4309Q34205401-9EB26F75-AAC6-4543-88C5-90C86EE6EBF0Q34376257-236F8B2F-E919-4C39-AEA0-22845075BF7AQ34379086-F809039D-5B55-403A-954D-7EE762A84204Q34435654-9BCCD0A9-B555-42F3-AC63-122A153DC04DQ34500304-F76DCDE2-922B-46FB-B27F-AB006F38135EQ34559926-D9447D01-8D4D-4D57-8EDC-71C828083EB7Q34573519-B2D87AC5-920D-4373-A122-25DC9636F0FDQ35039847-0EB07376-CE5F-4E04-A509-0ED806F9064CQ35079577-CB9513B2-7723-4504-BB8B-69AE74D0DBE2Q35106315-00DB7E77-F50C-4F10-836A-4D574A5AE1F0Q35126620-9EB86B7E-E545-490C-B312-04B7F8DF757BQ35252511-F2317D22-5E8B-46A2-903D-62F1A949173DQ35552418-7C5D5038-FF6C-40AD-B75F-05150C6A7EBFQ35612116-4A0576C4-A16D-4BB0-BE6E-E978FDF8B21EQ35709298-D508EE64-8A86-4360-8FC5-15CC5B2BBBCCQ35782236-83C1CD87-772A-43DB-85B1-1A550D6C1ECEQ35796384-A9382B38-1144-46A8-AF82-0CC244B114E9Q35874554-58E1783C-8D9A-4BF3-9FD7-F34429A4381BQ35939161-3ECB9C1E-B5F0-40D5-A0E2-846BAEA5C485Q36026570-74EAFEC8-4084-4E2F-A5F2-68472975AB5DQ36068428-5FFA0CED-1D55-4195-81D4-63ACE7B7EAF3Q36072526-2BCFD324-5FF0-416D-B0ED-6964C6D1F059Q36217451-744E74F6-D43F-4552-8FE4-BE73C972640CQ36222413-224AC4B9-5A8F-412D-88BD-906A7D7C6FC0Q36223090-3BF5513F-5153-4A3A-BD88-5C694E404B47Q36269761-6B5FB8BE-0CF8-478C-9DC5-825C86876C70Q36385275-23366466-9D90-4B91-8D99-990AF5374803
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Plasminogen activator inhibitors.
@en
Plasminogen activator inhibitors.
@nl
type
label
Plasminogen activator inhibitors.
@en
Plasminogen activator inhibitors.
@nl
prefLabel
Plasminogen activator inhibitors.
@en
Plasminogen activator inhibitors.
@nl
P1433
P1476
Plasminogen activator inhibitors.
@en
P2093
P304
P407
P577
1987-02-01T00:00:00Z